

# Sleep Bruxism: A Comprehensive Overview for the Dental Clinician Interested in Sleep Medicine

Maria Clotilde Carra, DMD<sup>\*</sup>, Nelly Huynh, PhD,  
Gilles Lavigne, DMD, PhD, FRDC

## KEYWORDS

- Sleep bruxism • Tooth grinding • Tooth clenching
- Sleep arousal • Sleep-disordered breathing • Headache
- Temporomandibular disorders

## DEFINITION AND CLASSIFICATION OF SLEEP BRUXISM

In dentistry, bruxism is traditionally considered an oral parafunction characterized by involuntary grinding and clenching of the teeth.<sup>1,2</sup> Although this definition describes the main characteristics of the disorder, it lacks a substantial and important distinction between the wake and sleep states in which this oral parafunction may occur. In fact, a wake-time habit of clenching, grinding, or gnashing the teeth seems to be a different nosologic entity, probably with a different cause and pathophysiology, and it should be distinguished from bruxism during sleep.

According to the American Academy of Sleep Medicine (AASM) (*International Classification of Sleep Disorders, Second Edition* [ICSD-II]),<sup>3</sup> sleep bruxism (SB) is

---

Disclosure of financial and conflicts of interest: M.C. Carra received a scholarship from the Ministère de l'Éducation, du Loisir et du Sport du Québec. G. Lavigne is a Canada Research Chair, and his research is supported by the Canadian Institutes of Health Research (CIHR grant MOP - 11701), FRSQ, and CFI. He has been an invited speaker, lecturer, or consultant with UCB Belgium, Pfizer (Wyeth) Canada and Medotech (Grindcare), Denmark. The authors' group also receives, free or at reduced cost, oral appliances for research purposes (ORM-Narval, France-Canada; Silencer, Canada; Klearway, Canada) with no obligation attached. N. Huynh declares no financial conflicts of interest.

Faculty of Dental Medicine, Université de Montréal, CP 6128 Succursale Centre-Ville, Montreal, Quebec, H3C 3J7, Canada

<sup>\*</sup> Corresponding author.

E-mail addresses: [maria.clotilde.carra@umontreal.ca](mailto:maria.clotilde.carra@umontreal.ca); [mclotildecarra@gmail.com](mailto:mclotildecarra@gmail.com)

Dent Clin N Am 56 (2012) 387–413


doi:[10.1016/j.cden.2012.01.003](https://doi.org/10.1016/j.cden.2012.01.003)

[dental.theclinics.com](http://dental.theclinics.com)

0011-8532/12/\$ – see front matter © 2012 Elsevier Inc. All rights reserved.

classified as a sleep-related movement disorder. The characteristic electromyography (EMG) pattern of SB is found in repetitive and recurrent episodes of rhythmic masticatory muscle activity (RMMA) of the masseter and temporalis muscles that are usually associated with sleep arousals.<sup>3,4</sup> RMMA shows a frequency of 1 Hz and typically occurs cyclically during sleep (Fig. 1).<sup>4</sup> RMMA episodes are observed in 60% of the general adult population as physiologic activity of the jaw muscles during sleep.<sup>5,6</sup> Many other forms of masticatory and facial muscle activity are also observed during sleep, such as swallowing, coughing, sleep talking, smiling, lip sucking, jaw movements, and myoclonus.<sup>4,7</sup> These orofacial activities account for approximately 85% of EMG events scored on the masseter and temporalis muscles in control subjects and 30% in patients with SB.<sup>5,8–10</sup> In fact, RMMA frequency is 3 times higher in patients with SB than in controls and is typically associated with tooth-grinding sounds (in 45% of cases), as reported by patients, bed partners, parents, or siblings.

SB may be an extreme manifestation of a physiologic orofacial motor behavior during sleep (RMMA and chewinglike activity) whereby certain factors increase its occurrence until it falls into the pathologic range of jaw-muscle activity.<sup>11,12</sup> Therefore, SB refers to the sleep motor disorder, whereas RMMA is the characteristic EMG pattern that is scored during sleep to make a polysomnographic diagnosis of SB.



**Fig. 1.** Hypnogram and polysomnographic tracing showing an episode of RMMA during sleep. The full-night hypnogram (graph in the upper left) represents sleep stage distribution in non-REM sleep 1, 2, 3, 4, and REM sleep, whereas the 20-second polysomnographic page shows a clear example of RMMA during sleep. The patient is in non-REM sleep stage 2. RMMA is defined when at least 3 consecutive EMG bursts (frequency 1 Hz) lasting greater than or equal to 0.25 seconds are scored on the masseter and temporalis channels. Corresponding with the RMMA episode, note the increased frequency in cortical activity (EEG central [C<sub>3</sub>A<sub>2</sub>] and occipital [O<sub>1</sub>A<sub>2</sub>] derivations), increased heart rate (on the ECG channel), and increased amplitude of respiratory airflow (naso-cannula). Immediately before the RMMA onset, a leg movement event is also seen on the EMG channel of the tibialis muscle. Airflow, naso-cannula airflow; C<sub>3</sub>A<sub>2</sub>, the central derivation of the electroencephalogram; ECG, electrocardiogram; EMG, electromyographic activity of the suprahyoid muscle; LOC, left electrooculogram; LegL, EMG of the left tibialis muscle; MasR and MasL, EMG of the right and left masseter muscles; Mic, microphone; O<sub>1</sub>A<sub>2</sub>, the occipital derivation of the EEG; ROC, right electrooculogram; SpO<sub>2</sub>, oxygen saturation level (expressed as %); TempR and TempL, EMG of the right and left temporalis muscles.

## ASSESSMENT AND DIAGNOSIS OF SB

The assessment and diagnosis of SB are often challenging. Generally, the assessment is based on reports of tooth-grinding sounds during sleep and the presence of clinical signs and symptoms.<sup>3</sup> However, only an EMG recording of the masticatory muscles can confirm the SB diagnosis. Several portable diagnostic tools have been developed to record masseter or temporalis EMG activity during sleep to avoid using the more sophisticated but highly cost- and time-consuming polysomnography (PSG). However, the reliability of most portable devices has not yet been validated, and their use may be considered only as support in a clinical assessment of SB. In fact, the SB diagnosis is usually clinical, although the gold standard remains a full-night PSG with audio-video recording (**Table 1**). The future direction for SB assessment would be to develop a handy tool that can directly, reliably, and rapidly measure ongoing bruxism activity and that can be used in both clinical (for diagnosis, treatment outcome evaluation, and follow-up) and research settings.

### *Clinical Diagnosis of SB*

The clinical diagnosis of SB should be based on the international diagnostic criteria proposed by the AASM (**Box 1**).<sup>3,13</sup> Grinding sounds caused by tooth contacts are the pathognomonic sign of SB and they are usually reported by patients, bed partners, siblings, or parents. However, not all RMMA episodes are accompanied by tooth grinding and many patients or family members may not be aware of this.

A clinical examination of the oral cavity allows identifying signs and symptoms that are markers of tooth-grinding activity and a clenching habit. These signs and symptoms include hypertrophy of the masseter and temporalis muscles, tongue indentation, tooth wear, jaw muscle tenderness or pain on digital palpation, and reports of morning headache.<sup>4,14</sup> However, none of these signs and symptoms constitutes direct proof of current SB activity. For example, although tooth wear is widely reported in the literature as the classic dental sign of bruxism (both awake and during sleep), it may be related to many other factors that can induce attrition and erosion on dental surfaces (eg, age, occlusal conditions, enamel characteristics, diet, carbonated drinks, medications, gastroesophageal reflux, and alimentary disorders).<sup>4,14–18</sup> Moreover, it was recently demonstrated that tooth wear cannot be used as an absolute criterion to assess SB severity: no difference in tooth wear grade was found between low and high frequency of muscle contractions in young adults with SB.<sup>16</sup>

During the clinical examination, dental clinicians can also identify early risk factors for SB and other sleep or medical disorders (eg, sleep-disordered breathing) and promote further investigations when necessary. In particular, the risk of having or developing sleep-disordered breathing (SDB) increases with retrognathia, micrognathia, macroglossia, adenotonsillar hypertrophy, and a Mallampati score of III and IV.<sup>19</sup> The Mallampati score qualifies oropharyngeal obstruction, with I standing for no obstruction (tonsils, pillars, and soft palate are clearly visible) and IV for high obstruction (only the hard palate is visible).<sup>20</sup> In addition, clinicians can directly observe breathing habits (mouth breathing vs nasal breathing), behavioral attitudes (agitation, anxiety), and a tendency to fall asleep. Although it remains under investigation, some of these factors have been associated with an increased risk for both SB and SDB.<sup>21</sup>

Appropriate questionnaires can also be used to investigate general health, quality of life, pain, headache, sleep quality, and sleepiness. Some questionnaires have been validated for both clinical and research purposes (eg, the Pittsburg Sleep Quality Index and the Epworth Sleepiness Scale). Questionnaire assessments may give the clinician

Table 1 Methods for assessing SB (order of increasing reliability)	
Method	Notes
Patient history	Many patients may not be aware of their tooth-grinding habit during sleep. It is more reliable if the bed partner, parents, or siblings report current tooth-grinding sounds during sleep
Clinical assessment	It is used to assess the clinical signs and symptoms that suggest SB (eg, tooth wear; see <b>Box 1</b> ) and the presence of potential risk factors for other comorbidities (eg, enlarged tonsils, skeletal class II, and Mallampati score III or IV for the risk of concomitant SDB)
Questionnaires	It is used to investigate patients' general and oral health, sleep quality, sleep habits, oral parafunctions, presence and characteristics of pain, headache, fatigue, depression, anxiety and stress, and comorbidities.
Ambulatory EMG monitoring	It allows recording EMG activity during sleep from the temporalis or masseter muscles, depending on the device used. However, there is very low specificity and sensitivity in distinguishing actual RMMA episodes from the many other orofacial and motor activities that occur during sleep. Furthermore, there is no monitoring on awakening from sleep, arousal, sleep staging, or other sleep variables. This tool could be valuable in the clinical assessment of SB and in large-sample studies (eg, general population epidemiologic studies)
Ambulatory PSG recording (type II, III, and IV)	It is usually performed at patients' homes. Normally, there is no audio-video monitoring; specificity and sensitivity in detecting RMMA depends on the device used, and more particularly, on the number of variables monitored (EEG, EOG, ECG, EMG, and respiratory channels). This method may be used for scoring sleep stages, sleep arousals, leg movements, and EMG activity, and for monitoring breathing
Full audio-video PSG recording (type I)	It remains the gold standard for the diagnosis of SB and the assessment of comorbidity with other sleep disorders (eg, SDB, PLMS, RLS, RBD, parasomnias). Normally, it allows full-night monitoring of EEG, EOG, EMG, ECG, leg movements, respiratory effort, airflow, and oxygen saturation. Concomitant audio-video recording increases the specificity and sensitivity in RMMA detection and scoring by distinguishing between RMMA episodes and orofacial (eg, swallowing, coughing, sleep talking) and other muscular activities (eg, head movements, eye blinking) that occur during sleep

*Abbreviations:* ECG, electrocardiogram; EEG, electroencephalogram; EOG, electrooculogram; PLMS, periodic limb movement during sleep; RBD, REM sleep behavior disorder; RLS, restless leg syndrome; SDB, sleep-disordered breathing.

*Data from* Lavigne G, Manzini C, Huynh NT. Sleep Bruxism. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th edition. St Louis (MO): Elsevier Saunders; 2011. p. 1129–39; and Hirshkowitz M, Kryger MH. Monitoring techniques for evaluating suspected sleep-disordered breathing. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th edition. St Louis (MO): Elsevier Saunders; 2011. p. 1610–23.

an indication of the risk of comorbidity between SB and other, more severe sleep disorders, such as SDB or restless leg syndrome (RLS) (see **Table 1**).

**Ambulatory Assessment of SB**

Several portable EMG monitoring systems have been developed to assess SB activity. They differ in degree of complexity, ranging from miniature self-contained EMG detectors to ambulatory PSG systems (type II, III, and IV),<sup>22</sup> which allow monitoring only a limited number of channels (see **Table 1**). These devices enable multiple-night

**Box 1****AASM clinical diagnostic criteria for SB***Patient history*

- Recent patient, parent, or sibling report of tooth-grinding sounds occurring during sleep for at least 3 to 5 nights per week in the last 3 to 6 months

*Clinical evaluation<sup>a</sup>*

- Abnormal tooth wear
- Hypertrophy of the masseter muscles on voluntary forceful clenching
- Discomfort, fatigue, or pain in the jaw muscles (and transient, morning jaw-muscle pain and headache)

Jaw-muscle activity cannot be better explained by another current sleep disorder, medical or neurologic disorder, medication use, or substance use disorder.

<sup>a</sup> None of these signs and symptoms constitutes direct proof of current SB activity. Full-night PSG with audio-video recording remains the gold standard for SB diagnosis.

*Data from* International classification of sleep disorders, 2nd ed.: Diagnosis and coding manual. (ICSD-2). Westchester, Illinois: American Academy of Sleep Medicine (AASM) eds.; 2005. Section on Sleep Related Bruxism. p.189–92; and Lavigne G, Manzini C, Huynh NT. Sleep Bruxism. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th edition. St Louis (MO): Elsevier Saunders; 2011. p. 1129–39.

recordings in patients' homes at minimal expense and could be useful research tools in large sample studies. However, the lack of standardized scoring criteria and evidence-based validity limit their application to both clinical and research settings.

Because automatic EMG detectors and analyzers usually use a unique algorithm for RMMA activity scoring, their validity remains to be demonstrated. Conversely, ambulatory PSG recordings provide very good quality EMG signals and, depending on their complexity, they can usually assess other sleep parameters, such as sleep electroencephalogram (EEG) (essential for sleep staging) or respiratory variables. In addition, on the masseter or temporalis EMG channels, RMMA episodes can be distinguished as phasic, tonic, or mixed. Furthermore, episode and burst frequency and muscular strength can be calculated (**Box 2**).<sup>4</sup> However, ambulatory PSG is usually performed in the patients' homes without audio-video monitoring. This situation may lead to the overestimation of RMMA episodes because of confounding and non-SB-specific motor activities during sleep. The authors are currently validating RMMA scoring criteria on ambulatory PSG recordings and have observed a modest concordance rate between RMMA scored with and without video on the same night (Carra, unpublished data, 2012). Although preliminary, this finding suggests that, in the absence of audio-video recording, more rigorous criteria should be applied to the clinical assessment and EMG scoring of SB-related activity.

***Polysomnographic Diagnosis of SB***

PSG for SB is mainly used for research purposes (see **Table 1**). The research diagnostic criteria have been developed from PSG with audio-video recordings performed in a hospital setting with a sleep technician attending full-night monitoring.<sup>9,13</sup> This PSG (referred to as type I)<sup>22</sup> allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between RMMA and orofacial (eg,

**Box 2****Polysomnographic research diagnostic criteria for SB for scoring RMMA episodes**

Mean EMG amplitude: at least 10% of maximum voluntary clenching activity

*Types of RMMA episodes*

- PHASIC: at least 3 EMG bursts lasting  $\geq 0.25$  seconds and  $< 2$  seconds
- TONIC: 1 EMG burst lasting  $> 2$  seconds
- MIXED: phasic and tonic bursts
- EMG bursts must be separated by  $< 2$  seconds to be considered part of the same episode.

*SB diagnosis can be made based on<sup>a</sup>*

- The RMMA INDEX: number of RMMA episodes per hour of sleep
- The BURST INDEX: number of EMG bursts per hour of sleep
- The BRUXISM TIME INDEX (%): total time spent bruxing/total sleep time  $\times 100$
- TOOTH-GRINDING SOUNDS: at least 1 RMMA episode with tooth-grinding sounds

*Positive SB diagnosis (based on the frequency of EMG episodes with positive tooth-grinding history or confirmation in a sleep laboratory)<sup>a</sup>*

- LOW FREQUENCY: when the RMMA index  $\geq 2$  and  $< 4$
- HIGH FREQUENCY: when the RMMA index is  $\geq 4$  or the burst index  $\geq 25$

<sup>a</sup> Best level of reliability when performing audio-video PSG recordings and the presence of at least 2 RMMA episodes associated with tooth-grinding sounds.

Data from Refs.<sup>3,4,9,23–26</sup>

swallowing) and other muscular activity (eg, head movements) during sleep. The validated criteria for a sleep laboratory diagnosis of SB showed 72% sensitivity and 94% specificity.<sup>9</sup> Based on the RMMA index (number of episodes per hour of sleep), SB is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism) (see **Box 2**).<sup>4,9,27</sup>

PSG recordings are not usually indicated for patients who report SB only. However, the clinician should refer patients to a sleep physician for further investigation and diagnosis if other sleep disorders are suspected (eg, sleep apnea, sleep-related epilepsy, rapid eye movement [REM] sleep behavior disorder, periodic limb movement, or other neurologic disorder).

## EPIDEMIOLOGY OF SB

In large population-based studies, it is difficult to assess SB by objective measures, such as PSG recordings. The epidemiology of SB is, therefore, largely determined by questionnaires, self-reports, or clinical findings (eg, tooth wear).

SB is reported by 8% of the general adult population.<sup>28,29</sup> It typically peaks during childhood (with prevalence approaching 40% in children aged less than 11 years)<sup>30–36</sup> and tends to decrease after adulthood. No gender difference has been observed.<sup>28,29,34,37</sup> SB is a common sleep disorder. However, the wide prevalence range reported in the literature is most probably because many studies failed to distinguish between wake-time and sleep-related bruxism or to assess the presence of medical comorbidities that may influence its occurrence. Indeed, SB is frequently concomitant (approximately one-third of patients) with wake-time bruxism, which is

characterized mainly by a tooth-clenching habit.<sup>38</sup> Wake-time bruxism tends to increase with age, with an estimated prevalence of 12% in children<sup>21,32</sup> and more than 20% in adults.<sup>32,39–41</sup>

CAUSE AND PATHOGENESIS OF SB

The exact cause and pathophysiology of SB are still unknown.<sup>42</sup> The putative etiologic mechanisms for SB genesis include sleep arousal, autonomic sympathetic-cardiac activation, genetic predisposition, neurochemicals, psychosocial components, exogenous factors, and comorbidities (Table 2).

Masticatory muscle movements during sleep (RMMA) are probably different from chewing activity while awake. In fact, SB is characterized by rhythmic motor activity

Table 2 Cause and pathophysiology of SB	
Putative Etiologic Factors and Mechanisms	Evidence <sup>a</sup>
Sleep arousal More than 80% of RMMA episodes occur in association with sleep arousal. However, sleep arousal is considered the permissive window that facilitates RMMA occurrence during sleep rather than a trigger or cause of SB	+++
Autonomic sympathetic cardiac activity An increase in sympathetic cardiac activity precedes the onset of most RMMA episodes. This increase is also followed by an increase in heart rate and blood pressure immediately before the muscular activity of the jaw opening and closing muscles	+++
Neurochemicals The potential role of catecholamines (adrenaline, noradrenalin, and dopamine); Patients with SB seem to have higher urinary levels of catecholamines. The putative role of other neurochemicals includes: gamma-aminobutyric acid, orexin, serotonin, and acetylcholine (all involved in the genesis and maintenance of wake and sleep; as yet unknown roles)	+
Genetic and familial predisposition In more than 80% of cases, SB persists from childhood to adulthood. Higher concordance in monozygotic than dizygotic twins. Approximately one-third of patients with SB have a direct family member with a positive tooth grinding history	+
Psychosocial factors Anxiety and stress are risk factors for SB. Patients with SB seem to have maladaptive coping strategies and a more task-oriented personality than patients without SB.	++
Exogenous factors Alcohol, caffeine, cigarette smoking, illicit drug use (eg, cocaine, ecstasy), and medication intake (eg, SSRI) can trigger or increase wake-time bruxism and SB activity	++
Comorbidity A common underlying pathogenetic mechanism is suspected (eg, SB and SDB: does SB play a role in reinstating airway patency following an apnea event, or is SB an apnea-related arousal reaction?)	++

Abbreviation: SSRI, selective serotonin reuptake inhibitor.  
+, weak evidence; ++, moderate evidence; +++, strong evidence.  
<sup>a</sup> Strength of available scientific evidence.  
Data from Refs.<sup>4,15,42,44,48,52,58,70,72,76,78,99,114</sup>

that occurs without any food triturating purpose and is associated with co-contraction of both the jaw-closing and jaw-opening muscles. Moreover, although SB occurs without apparent cortical involvement, unlike chewing, which is initiated at the cortical level, it is strongly influenced by autonomic nervous system activity and arousals during sleep.<sup>15,43</sup> Nevertheless, many scientific studies suggest that SB is centrally regulated, probably in the brainstem, and its genesis is more likely multifactorial.<sup>4,44–46</sup> Conversely, there is little scientific evidence to support a predominant role for peripheral factors, such as occlusal interferences, in the cause of SB.<sup>47</sup>

### ***Sleep Arousal***

According to the ICSD-II definition, most RMMA episodes (75%–88%) occur in association with sleep arousals.<sup>3,13,48</sup> This association was first observed by Reding and colleagues<sup>49</sup> in 1968 and by Satoh and Harada<sup>50</sup> in 1971, who described tooth-grinding activity as an arousal reaction. Since then, many studies have used polysomnography and electrophysiology to investigate the complex relationship between SB and sleep arousal.<sup>11,12,42,48,51–53</sup> Sleep arousal is defined as a brief awakening from sleep (for at least 3 seconds) characterized by increased EEG, autonomic, cardiac, and muscular activities without a complete return to consciousness.<sup>13</sup> Arousals normally reoccur from 6 to 14 times per hour of sleep as the response of the sleeping brain to external (environmental) and internal (physiologic or pathologic) stimuli. Recent evidence on the pathophysiology of SB supports the hypothesis that the frequency of RMMA episodes is modulated by the cyclic occurrence of sleep arousals, called the cyclic alternating pattern (CAP).<sup>12,42,48,49,52</sup> CAP is scored on non-REM sleep EEG to identify periods of stable sleep (phase B) that alternate with periods of active and unstable sleep (phase A, arousal).<sup>54,55</sup>

RMMA episodes are observed more frequently in non-REM sleep stages 1 and 2 (light sleep), in sleep stage shifts, and especially in the transition period from non-REM to REM sleep.<sup>4,48,52,56</sup> More than 80% of RMMA episodes are time correlated with CAP phase A, and they recur in rhythmic clusters, with a periodicity of 20 to 30 seconds, which is similar to the physiologic arousal rhythm of CAP.<sup>12,48,52</sup> Notwithstanding this strong association between sleep arousal and SB, sleep arousals (and CAP phase A) are neither the cause nor the trigger of SB. Instead, they constitute the permissive window that facilitates RMMA during sleep.<sup>12,56</sup>

### ***Autonomic Sympathetic-Cardiac Activity***

Recent evidence on SB pathophysiology highlights the role of the autonomic nervous system.<sup>42,46,57</sup> It has been well demonstrated that RMMA onset is associated with a sequence of physiologic events that occur within a sleep arousal. Briefly, the genesis of most RMMA episodes is preceded by the following cascade of events<sup>4</sup>:


- An increase in the autonomic sympathetic-cardiac activity with a concomitant withdrawal of parasympathetic influences (from 8 to 4 minutes before RMMA onset)<sup>52</sup>
- The appearance of rapid-frequency EEG cortical activity (sleep arousal; approximately 4 seconds before RMMA onset)<sup>42</sup>
- An approximately 25% increase of heart rate (beginning 1 second before RMMA onset), concomitant with
- An increase in EMG activity of the jaw opener muscle (eg, the suprahyoid muscle, probably responsible for mandible protrusion and airway opening), concomitant with
- An increase in the airflow amplitude visible as two big breaths preceding or concomitant with<sup>58</sup>

- An increase in diastolic and systolic blood pressure<sup>59</sup>
- An observable EMG incident in the jaw-closing muscles (masseter and temporalis), scored as RMMA with or without tooth-grinding sounds<sup>4</sup>; Almost 60% of RMMA episodes are followed in the 5 to 15 seconds after onset by swallowing (Fig. 2).<sup>60</sup>

### Neurochemicals

Many neurochemicals and neurotransmitters may be involved in the genesis and modulation of jaw movements during sleep, especially those that participate in controlling motoneuron activity and regulating sleep and wake states (acetylcholine, noradrenalin, dopamine, orexin).<sup>44,61</sup> The dopaminergic system was first investigated after the early observation of tooth-grinding activity in a patient with Parkinson disease treated with L-dopa.<sup>62</sup> However, further studies using the dopamine precursor, L-dopa, and the dopaminergic agonist, bromocriptine, demonstrated only a modest effect of dopamine-related medications on SB.<sup>63–65</sup> Dopamine is not usually very active during sleep but it may be linked to sleep arousal reactivation.<sup>66</sup> Conversely, clonidine, an adrenergic agonist, reduced RMMA episodes by 60%, supporting the role of sympathetic-cardiac activation, adrenaline, and noradrenalin in SB genesis.<sup>67</sup> Because noradrenergic action is critical during non-REM sleep in the minutes preceding REM sleep onset, it may participate in the transition from non-REM to REM sleep, a state associated with muscle hypotonia.<sup>68</sup>

Other neurotransmitters, such as serotonin, gamma-aminobutyric acid, cholecystokinin, and orexin, may have a role in modulating RMMA during sleep. Ionic channels, receptors, and their cellular expression may also be involved in SB genesis. However,



**Fig. 2.** Genesis of an RMMA episode. The cascade of physiologic events that precedes RMMA onset is shown (schematic representation). A detailed explanation is provided in the text. BP, blood pressure; ECG, electrocardiogram; LM, laryngeal movements; SH, EMG of the suprahyoid muscle; Mas-R and Mas-L, EMG of the right and left masseter muscles. (Data from Refs. <sup>11,42,52,53,58,59</sup>)

either data are not yet available or the findings are supported by indirect evidence only, derived from case reports on drug and medication use. Prospective and randomized control experimental trials are needed before firm conclusions can be drawn on neurochemical participation in SB genesis.

### ***Genetic Factors***

There is little evidence for a genetic predisposition for SB. Children of patients with SB are more likely to be affected than children of individuals who never had SB or who suffer from wake-time bruxism only.<sup>69</sup> From 20% to 50% of patients with SB have a direct family member who ground his or her teeth in childhood, and childhood SB persists in adulthood in 87% of patients.<sup>70,71</sup> In a Finnish twin cohort study, higher concordance was found among monozygotic than dizygotic twins.<sup>71,72</sup>

Despite this early evidence of a genetic basis for SB, the inheritance pattern remains unknown, and no genetic marker has been identified to date. Further research on population-based samples is needed to explore and delineate the probable genetic component in SB genesis. It would be more likely related to genetic polymorphism than a single gene mechanism. Moreover, links to other wake and sleep behaviors would probably emerge.<sup>73,74</sup> It is worth noting that SB assessment tools in large populations, frequently based on a positive history of tooth grinding alone, have yet to be validated for acceptable sensitivity and specificity, especially in the general population. A clinical diagnosis of SB supported with portable systems or single-channel EMG recording is feasible and promising but still lacking in specificity.

### ***Psychosocial Factors: Stress, Anxiety, and Behavior***

Aside from a probable genetic predisposition, many other causal or risk factors may play a role in the genesis of SB activity. Psychosocial components in particular, such as anxiety and stress, have frequently been associated with SB.<sup>29,75–79</sup> Both child and adult patients reporting SB were found to have higher levels of urinary catecholamines (adrenaline, noradrenaline, dopamine) than controls.<sup>80–82</sup> These results were attributed to stress factors that activate the hypothalamic-adrenal axis, which controls the catecholamine release. Other studies, mainly questionnaire based, suggest that patients with SB may have maladaptive coping strategies: they seem to be more anxious, stressed, and task oriented as a result of their personality and coping style (eg, type A personality).<sup>29,75,77,78,83,84</sup> Especially in children, SB has been associated with behavioral habits and complaints. These complaints include neuroticism, perfectionism, aggressiveness, lack of concentration and attention (eg, at school), thought disorders, antisocial behaviors, and conduct disorders.<sup>21,85–87</sup> Moreover, all these psychosocial factors have been related to wake-time bruxism.<sup>21</sup> In fact, tooth clenching may be an adaptive or reactive learning behavior (to cope with stress, anxiety, and social life) that may also occur during sleep. However, the overlapping and interactions between wake-time and sleep-time bruxism are still matters of debate.

Alternatively, SB has been considered a tic, an automatism, a movement fragment, or tardive dyskinesia, which may manifest during wake time and persist during sleep.<sup>88</sup> In any case, the many and contrasting findings in the literature indicate that further research is needed to better understand the role of psychosocial factors in SB pathophysiology.<sup>74,76</sup>

### ***Exogenous Factors and Comorbidities***

Several exogenous factors and medical conditions have been associated with SB or bruxismlike activities during either sleep or wake time. The exogenous risk factors for

SB include alcohol consumption, cigarette smoking, caffeine intake, medication use (eg, selective serotonin reuptake inhibitor [SSRI]), and drug use (eg, ecstasy).<sup>29,89–99</sup> SB may also be observed in comorbidity with medical disorders, such as attention-deficit/hyperactivity disorder (ADHD)<sup>100,101</sup>; movement disorders (eg, Parkinson disease and Huntington disease)<sup>102,103</sup>; dementia<sup>104–106</sup>; epilepsy<sup>107–109</sup>; gastroesophageal reflux<sup>110</sup>; and other sleep disorders, such as parasomnias (eg, sleep walking, sleep talking, enuresis, REM sleep behavior disorder [RBD]), periodic limb movements (PLM), RLS, and SDB (**Box 3**).<sup>111–115</sup> It remains to be assessed, however, whether these are cases of intersecting prevalence between 2 parallel disorders or if one condition causes or exacerbates the other.<sup>116</sup>

When SB is associated with medication or drug intake or with medical diseases, it is defined as secondary or iatrogenic SB. Conversely, in the absence of medical causes, SB is considered to be primary, or idiopathic, and it can in turn lead to several clinical consequences on the stomatognathic system, such as tooth wear, tooth damage, tooth fractures, muscle fatigue, orofacial pain, temporomandibular disorders (TMD), and headache.<sup>4</sup>

Box 3
SB and comorbidities
Parasomnias
Enuresis
Sleep talking
Sleep walking
RBD
Other sleep-related disorders
Sleep-disordered breathing (snoring, obstructive sleep apnea)
Sleep-related epilepsy
PLM and RLS
Sleep-related gastroesophageal reflux
Medical and psychological conditions
Hypertrophic tonsils or adenoids
Allergies
ADHD
Headaches
Orofacial pain and temporomandibular disorders
Stress and anxiety
Neurologic and psychiatric disorders (eg, dementia, depression)
Movement disorders (eg, Parkinson disease, oromandibular dystonia, tics)
Oral habits and parafunctions
Tics
Nail biting, pen biting, and so forth
Wake-time tooth clenching
Data from Refs. <sup>23,100–102,107,108,110,115,117–120</sup>

**SB, Orofacial Pain, and TMD**

Orofacial pain is reported by from 66% to 84% of patients with SB.<sup>117,118</sup> However, the presence or intensity of pain does not seem to be directly correlated with the frequency of RMMA episodes.<sup>23,119,121</sup> In fact, patients with SB with a low frequency of RMMA (2–4 episodes per hour of sleep) seem to have higher risks for orofacial pain and headache than patients with SB with a high frequency of RMMA (>4 episodes per hour of sleep).<sup>23,122</sup> Furthermore, note that SB may coexist with wake-time tooth clenching and other oral parafunctions (eg, lip, cheek, or nail biting), which can also cause or contribute to the development and persistence of orofacial pain.<sup>123–128</sup>


SB has been largely considered a sign or cause of TMD in both adult and pediatric populations.<sup>129–134</sup> Several studies suggest that SB may play a role in TMD genesis, especially the myogenous component, because of muscle hyperactivity during sleep. Nevertheless, TMD pain and morning jaw-muscle pain may be different entities. Most patients with TMD report a pain intensity peak in the late afternoon, whereas patients with SB report transient masseter and temporalis muscle pain or soreness mainly in the morning.<sup>23,135,136</sup>

**SB and Headaches**

SB has been frequently associated with headaches.<sup>21,113,120,137–141</sup> In a questionnaire-based study, children with SB reported approximately 3 times more headaches than control subjects, with an odds ratio of 4.3.<sup>21</sup> From 30% to 50% of adult patients with SB complain of headache either in the morning (most frequently) or during the day.<sup>138</sup> However, the exact mechanism underlying the possible interactions between SB and headaches remains unknown. It can be hypothesized that SB, which is characterized by repetitive rhythmic and sustained contractions of the masticatory muscles during sleep, may cause tension-type headaches during the daytime. In fact, this comorbidity is controversial because of the overlap with forms of TMD pain and TMD-related headaches.<sup>142,143</sup> Furthermore, the presence of an underlying sleep disorder, such as SDB, has often been associated with both SB and headache. In this latter case, the role of intermittent hypoxia and hypercapnia and sleep fragmentation (after obstructive respiratory events) may be the actual cause of the headaches (Fig. 3). Alternatively, SB, headache, and SDB may share common risk factors or pathophysiological substrates without a specific cause-and-effect relationship. For example, it has been shown that children with headaches frequently have concomitant sleep problems, such as SB and SDB, and a higher incidence of TMD.<sup>144,145</sup>

**SB and SDB**

Although SB and SDB (eg, upper airway resistance, obstructive sleep apnea [OSA], and central sleep apnea) have frequently been associated, the possible cause-and-effect relationship has not yet been elucidated.<sup>29,146–148</sup> Two open clinical studies and one case report have provided indirect evidence for this relationship by showing



**Fig. 3.** Comorbid SB, headache, and SDB: putative mechanisms.

a decrease in SB after different SDB treatments (eg, adenotonsillectomy and continuous positive airway pressure).<sup>149–151</sup> These findings support the hypothesis that RMMA may be an oromotor activity that helps reinstate airway patency following an obstructive respiratory event during sleep.<sup>58</sup> An alternative hypothesis considers RMMA a physiologic motor event that is required to lubricate the oropharyngeal structures during sleep, a period when salivary flow and swallowing rate are normally reduced.<sup>60,152</sup> The factors that induce RMMA to reach abnormal frequency in patients with SB remain to be elucidated.

## MANAGEMENT OF SB

No therapy to date has been proven effective to cure SB. The available treatment approaches aim at managing and preventing the harmful consequences of SB to the orofacial structures (**Table 3**).<sup>153</sup>

### *Behavioral Strategies*

SB can be managed by behavioral strategies, including the avoidance of SB risk factors and triggers (eg, consumption of tobacco, alcohol, caffeine, and drugs), patient education (eg, control of wake-time oral parafunctions), relaxation techniques, sleep hygiene, hypnotherapy, biofeedback, and cognitive behavioral therapy.<sup>154–158</sup> However, most of these strategies have not been adequately tested in controlled trials. Nevertheless, a recent study showed that a new biofeedback device that applies electrical pulses to inhibit EMG activity in the temporalis muscle was effective in the short term in reducing EMG activity during sleep, without disrupting sleep quality.<sup>155</sup> In addition, a 12-week cognitive behavioral therapy session with patients with SB was found to reduce SB but showed no significant benefits over occlusal splint therapy.<sup>156</sup> Although these behavioral techniques have not yet shown clear or persistent effects, they seem to improve patients' well being and should be considered the first-line management approach in patients with SB.

### *Oral Appliances*

To protect dental surfaces and relax the masticatory muscles, occlusal splints, either on the maxillary or the mandibular arch, have been extensively used in clinical practice. However, the exact mechanism of action is still under debate and there is no evidence to support their role in halting SB. Moreover, the lack of well-designed randomized controlled clinical trials and long-term studies in the literature makes it difficult to assess their effectiveness.<sup>159</sup> Most studies show a decrease (40%–50%) in the RMMA index in the first period of treatment (2–6 weeks), regardless of the type of occlusal splint.<sup>24,160–162</sup> However, the effect seems to be transitory, with values returning to baseline after a short time and the outcomes are highly variable between patients. Moreover, it has been reported that approximately 20% of patients with SB show increased EMG activity during sleep when wearing an occlusal splint, especially the soft mouth guard type.<sup>163</sup>

Occlusal and anterior tooth appliances (eg, the nociceptive trigeminal inhibition system, NTI [<http://www.nti-tss.com>]) are also used in cases of SB comorbid with orofacial pain and TMD to relief muscle and joint pain.<sup>164–168</sup> Their effectiveness is still controversial because they rarely halt RMMA occurrence.<sup>169</sup> However, it has been hypothesized that these devices may make patients more conscious of their oral parafunctional habits by altering proprioceptive inputs, thus, helping them reduce clenching activity, albeit mainly during wake time.<sup>170,171</sup> Patients with TMD seem to find relief with occlusal splints compared with other or no treatment, especially the most severe

Table 3 Management of SB		
Clinical Approach	Functions	Potential Side Effects
Behavioral strategies		
<ul style="list-style-type: none"><li>• Patient education, sleep hygiene, relaxation techniques, hypnotherapy, biofeedback, and cognitive behavioral therapy</li></ul>	<ul style="list-style-type: none"><li>• Avoid SB risk factors (eg, smoking, alcohol, caffeine, drugs)</li><li>• Control wake-time oral parafunctions</li><li>• Improve sleep habits and sleep environment</li><li>• Control and reduce stress and anxiety (coping)</li><li>• Relax muscles and reduce EMG activity during sleep</li></ul>	<ul style="list-style-type: none"><li>• None identified to date</li></ul>
Intraoral appliances		
<ul style="list-style-type: none"><li>• Occlusal or stabilization splint</li><li>• NTI</li></ul>	<ul style="list-style-type: none"><li>• Protect tooth surfaces</li><li>• Reduce EMG activity (?)</li></ul>	<ul style="list-style-type: none"><li>• Impaired occlusion<sup>a</sup></li><li>• Increased SB activity</li><li>• Posterior dental overeruption or anterior dental intrusion (for NTI)<sup>a</sup></li></ul>
<ul style="list-style-type: none"><li>• Mandibular advancement appliances (commonly used for snoring and mild to moderate OSA)</li></ul>	<ul style="list-style-type: none"><li>• Reposition and stabilize the lower jaw, tongue, and soft tissues</li><li>• Open the upper airway space</li></ul>	<ul style="list-style-type: none"><li>• Excessive salivation or dry mouth</li><li>• Tenderness in the teeth, TMJ, muscles</li><li>• Perception of abnormal occlusion in the morning</li><li>• Occlusal changes (eg, reduced overjet and overbite)<sup>a</sup></li></ul>
Pharmacotherapy (recommended in the short term only)		
	<ul style="list-style-type: none"><li>• Reduce SB activity + extra effects related to the kind of medication used (eg, hypnotic, analgesic)</li></ul>	<p>Depends on the medication used:</p> <ul style="list-style-type: none"><li>• Clonazepam: tolerance, physiologic dependence, fatigue, somnolence</li><li>• Clonidine: hypotension</li><li>• Botulinum toxin: risk of retrograde transportation from the site of injection to CNS with systemic side effects</li></ul>

*Abbreviations:* CNS, central nervous system; NTI, nociceptive trigeminal inhibition system; TMJ, temporomandibular joint.

<sup>a</sup> Only in long-term treatment.

*Data from* Lavigne G, Manzini C, Huynh NT. Sleep Bruxism. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th edition. St Louis (MO): Elsevier Saunders; 2011. p. 1129–39.

cases with TMD pain.<sup>172</sup> Physiotherapy sessions targeting the masticatory muscles may also be useful in cases of SB associated with orofacial pain or TMD.<sup>173,174</sup>

It is worth mentioning that occlusal appliances and anterior tooth splints are not free of unwanted side effects, including changes in dental occlusion, single tooth

positioning, dental hypersensitiveness, and worsening of orofacial pain and SDB.<sup>175</sup> For example, in a pilot study of 10 patients with OSA, a maxillary occlusal splint was found to increase the hypopnea/apnea index in half of the patients, probably by reducing the intraoral space for the tongue, which changes the tongue position during sleep.<sup>175</sup> When SB is concomitant with OSA, or when SDB are suspected, a mandibular occlusal splint (custom made for the lower jaw) or a mandibular advancement appliance (MAA) would be preferable.

MAAs, which are currently used to treat snoring and mild to moderate forms of OSA, have also been tested in the short term to challenge the role of the airways in the genesis of RMMA episodes and to assess therapeutic benefits in patients with SB. An MAA was demonstrated effective in decreasing SB (up to 70%), especially when worn in advanced positions (50%–75% of the maximal protrusion).<sup>176,177</sup> They also seem to relieve daily morning headaches in patients with a low frequency of RMMA during sleep.<sup>178</sup> Although the use of an MAA for SB showed good effectiveness,<sup>153</sup> all these studies assessed the effect after short-term treatment only (2 weeks average). It remains to assess their effectiveness and side effects in long-term studies.<sup>179,180</sup>

### **Pharmacotherapy**

Several medications and drugs have been associated with decreased or increased SB activity, supporting the probability of central mechanisms for SB genesis (**Box 4**).<sup>89</sup> In particular, the dopaminergic, serotonergic, and adrenergic systems are thought to be involved in this orofacial motor activity. However, evidence is lacking on both the effectiveness and safety of using medications in patients with SB. Therefore, in symptomatic and most severe patients, pharmacologic treatments should be considered as a short-term therapy only.<sup>4</sup>

A recent placebo-controlled study demonstrated a 40% reduction in SB activity with an acute dose of clonazepam (1 mg).<sup>181,182</sup> Clonazepam is a benzodiazepine with hypnotic, anxiolytic, anticonvulsive, and myorelaxant effects. It acts at various levels of the central nervous system. The beneficial effect on SB genesis may result from actions on different systems linked to muscle activity, emotions, and behaviors. However, there are no available data on long-term treatment or potential side effects, such as sleepiness (risk of transportation or work-related accidents), pharmacobehavioral tolerance, and dependence.

Antidepressant drugs have also been recommended for SB as well as for chronic orofacial pain. However, there is little evidence to support their use. Low doses of amitriptyline (a tricyclic antidepressant) were found to be ineffective against SB,<sup>189,190</sup> and SSRI medications (eg, fluoxetine, sertraline, paroxetine) actually increased tooth grinding and clenching.<sup>95,183,191</sup>

Adrenergic beta-blockers, such as propranolol, were shown to be ineffective on SB.<sup>67</sup> Conversely, an acute dose (0.3 mg) of the  $\alpha_2$ -adrenergic agonist, clonidine, reduced SB by 60%, supporting the role of autonomic cardiac activation in the genesis of this sleep-related motor disorder. However, clonidine is associated with sleep structure changes (eg, less REM sleep) and severe morning hypotension.<sup>56,67</sup> Its use for SB therapy is highly controversial.

Anecdotal reports suggest a positive effect on SB of gabapentin,<sup>184</sup> tiagabine,<sup>192</sup> buspirone,<sup>193</sup> topiramate,<sup>185</sup> and botulinum toxin.<sup>186,187</sup> However, their effectiveness and safety need to be assessed in randomized controlled clinical trials. Potential candidates for more specific or more potent medications are substances that regulate the wake-sleep balance (eg, acetylcholine, noradrenaline, dopamine, orexin, histamine, serotonin), ionic channels, and cellular receptors (on neurons and glia).

Box 4

Effect of medications and chemical substances on SB or SB-like activity<sup>a</sup>

Increased SB activity

- SSRI (eg, paroxetine, fluoxetine, sertraline)
- Norepinephrine-selective reuptake inhibitors (eg, venlafaxine)
- Antipsychotic (eg, haloperidol)
- Flunarizine
- Amphetamines (eg, methylphenidate)
- 3,4-methylenedioxymethamphetamine (ecstasy)
- Cocaine
- Caffeine
- Nicotine
- Alcohol

Decreased SB activity

- Clonazepam
- Diazepam
- Methocarbamol
- Buspirone
- Levodopa
- Pergolide
- Clonidine
- Gabapentin
- Topiramate
- Botulinum toxin

No effect on SB activity


- Propranolol, bromocriptine, L-tryptophan

<sup>a</sup> The scientific evidence is based primarily on case reports (except for 2 randomized controlled clinical trials with PSG [Huynh 2006; Saletu 2010]). No long-term studies have assessed safety or benefits.

Data from Refs. [64,67,89–91,97,181–188](#)

SUMMARY

SB is a common sleep-related disorder that can be highly distressing because of several harmful consequences to the stomatognathic system, including tooth damage, headaches, muscle pain, and TMD. Dental clinicians are responsible for detecting and preventing these detrimental consequences to patients’ oral health. However, SB is much more than tooth wear. Patients with SB need to be screened for other comorbid medical conditions (eg, SDB, insomnia, ADHD, depression, mood disorders, gastroesophageal reflux) before undertaking any treatment approach, especially pharmacotherapy. Because underlying disorders and medication intake may interfere with motor activities during sleep, they need to be assessed before other treatments are recommended. Furthermore, if a medical comorbidity is



**Fig. 4.** Algorithm for the clinical assessment and management of SB.

diagnosed (eg, SDB), the therapeutic approach should primarily address the medical disorder while managing the consequences of SB (**Fig. 4**).

## CASE STUDY

### History and Clinical Examination

A 43-year-old woman complains about tooth grinding during sleep almost nightly. The patient has normal weight and no medical or neurologic diseases but smokes approximately 20 cigarettes a day. She judges herself as highly stressed at work. She reports occasional transient morning jaw-muscle pain, a sensation of jaw locking, and uncomfortable dental occlusion on awakening. However, these symptoms tend to disappear after 30 to 60 minutes and they do not particularly disturb the patient's quality of life. The patient reports good quality of sleep, but tooth-grinding noises and moderate snoring disturb her husband's sleep. The patient's chief complaint is the severe tooth damage she has observed on her dental surfaces, with a negative impact on her esthetic profile, to the point that she does not feel like smiling anymore.

### Assessment and Diagnosis

At the clinical examination, severe tooth wear, masseter muscle hypertrophy, and mild pain on palpation at the lateral pterygoid muscles are observed. The patient presents a dental and skeletal class II, a narrow and deep palate, and a Mallampati score of III. The Epworth Sleepiness Scale score indicates a low likelihood of daytime sleepiness, and no other SDB-related signs or symptoms are charted. Based on the patient's and her husband's reports of tooth-grinding sounds and the presence of relevant signs and symptoms, the patient is clinically diagnosed with SB and anatomic predisposition for SDB (history of snoring, retrognathia, and narrow and deep palate, Mallampati III). A PSG evaluation is not mandatory at the moment because the patient does not present any SDB-related symptoms (except for snoring). However, a long-term follow-up is recommended because the risk of SDB increases in women after menopause.

### ***Suggested Clinical Management***

The patient should be informed on the characteristics and consequences of SB as well as the available management options. First, cigarette smoking and other possible triggers should be avoided or reduced. Behavioral strategies should be tried to decrease stress, improve coping strategies, and relax the masticatory muscles. To control and prevent tooth wear, an intraoral appliance is recommended. However, because the patient is already a snorer and presents anatomic risk factors for SDB, an MAA would be preferable to an occlusal or stabilization splint. To address esthetic concerns, conservative and prosthodontic treatments should be planned. Follow-up visits must be scheduled to customize and adjust the MAA, verify the patient's general and oral status (stress level), and prevent SB consequences (tooth wear, pain) from worsening.

### **REFERENCES**

1. The glossary of prosthodontic terms. *J Prosthet Dent* 2005;94(1):10–92.
2. De Leeuw R. Orofacial pain. Guidelines for assessment, diagnosis and management. 4th edition. Chicago: Quintessence; 2008.
3. American Academy of Sleep Medicine (AASM), editor. International classification of sleep disorders. Diagnosis and coding manual. (ICSD-2). Section on sleep related bruxism. 2nd edition. Westchester(IL): American Academy of Sleep Medicine; 2005. p. 189–92.
4. Lavigne G, Manzini C, Huynh NT. Sleep bruxism. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th edition. St Louis (MO): Elsevier Saunders; 2011. p. 1129–39.
5. Lavigne GJ, Rompre PH, Poirier G, et al. Rhythmic masticatory muscle activity during sleep in humans. *J Dent Res* 2001;80(2):443–8.
6. De Laat A, Macaluso GM. Sleep bruxism as a motor disorder. *Mov Disord* 2002; 17(Suppl 2):S67–9.
7. Kato T, Thie NM, Montplaisir JY, et al. Bruxism and orofacial movements during sleep. *Dent Clin North Am* 2001;45(4):657–84.
8. Dutra KM, Pereira FJ Jr, Rompre PH, et al. Oro-facial activities in sleep bruxism patients and in normal subjects: a controlled polygraphic and audio-video study. *J Oral Rehabil* 2009;36(2):86–92.
9. Lavigne GJ, Rompre PH, Montplaisir JY. Sleep bruxism: validity of clinical research diagnostic criteria in a controlled polysomnographic study. *J Dent Res* 1996;75(1):546–52.
10. Walters AS, Lavigne G, Hening W, et al. The scoring of movements in sleep. *J Clin Sleep Med* 2007;3(2):155–67.
11. Kato T, Rompre P, Montplaisir JY, et al. Sleep bruxism: an oromotor activity secondary to micro-arousal. *J Dent Res* 2001;80(10):1940–4.
12. Carra MC, Rompre PH, Kato T, et al. Sleep bruxism and sleep arousal: an experimental challenge to assess the role of cyclic alternating pattern. *J Oral Rehabil* 2011;38(9):635–42.
13. Iber C, Ancoli-Israel S, Chesson A, et al. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Westchester (IL): American Academy of Sleep Medicine (AASM); 2007.
14. Koyano K, Tsukiyama Y, Ichiki R, et al. Assessment of bruxism in the clinic. *J Oral Rehabil* 2008;35(7):495–508.
15. Lavigne GJ, Khoury S, Abe S, et al. Bruxism physiology and pathology: an overview for clinicians. *J Oral Rehabil* 2008;35(7):476–94.

16. Abe S, Yamaguchi T, Rompre PH, et al. Tooth wear in young subjects: a discriminator between sleep bruxers and controls? *Int J Prosthodont* 2009;22(4):342–50.
17. Johansson A, Johansson AK, Omar R, et al. Rehabilitation of the worn dentition. *J Oral Rehabil* 2008;35(7):548–66.
18. Pergamalian A, Rudy TE, Zaki HS, et al. The association between wear facets, bruxism, and severity of facial pain in patients with temporomandibular disorders. *J Prosthet Dent* 2003;90(2):194–200.
19. Chan AS, Lee RW, Cistulli PA. Sleep-related breathing disorders. In: Lavigne GJ, Cistulli PA, Smith MT, editors. *Sleep medicine for dentists. A practical overview*. Hanover Park (IL): Quintessence Publishing Co, Inc; 2009. p. 35–40.
20. Philip P, Gross CE, Taillard J, et al. An animal model of a spontaneously reversible obstructive sleep apnea syndrome in the monkey. *Neurobiol Dis* 2005;20(2):428–31.
21. Carra MC, Huynh N, Morton P, et al. Prevalence and risk factors of sleep bruxism and wake-time tooth clenching in a 7- to 17-yr-old population. *Eur J Oral Sci* 2011;119(5):386–94.
22. Hirshkowitz M, Kryger MH. Monitoring techniques for evaluating suspected sleep-disordered breathing. In: Kryger MH, Roth T, Dement WC, editors. *Principles and practice of sleep medicine*. 5th edition. St Louis (MO): Elsevier Saunders; 2011. p. 1610–23.
23. Rompre PH, Daigle-Landry D, Guitard F, et al. Identification of a sleep bruxism subgroup with a higher risk of pain. *J Dent Res* 2007;86(9):837–42.
24. van der Zaag J, Lobbezoo F, Wicks DJ, et al. Controlled assessment of the efficacy of occlusal stabilization splints on sleep bruxism. *J Orofac Pain* 2005;19(2):151–8.
25. Ikeda T, Nishigawa K, Kondo K, et al. Criteria for the detection of sleep-associated bruxism in humans. *J Orofac Pain* 1996;10(3):270–82.
26. Gallo LM, Lavigne G, Rompre P, et al. Reliability of scoring EMG orofacial events: polysomnography compared with ambulatory recordings. *J Sleep Res* 1997;6(4):259–63.
27. Koyano K, Tsukiyama Y. Clinical approach to diagnosis of sleep bruxism. In: Lavigne GJ, Cistulli PA, Smith MT, editors. *Sleep medicine for dentists. A practical overview*. 1st edition. Hanover Park (IL): Quintessence Publishing Co, Inc; 2009. p. 109–16.
28. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. *Sleep* 1994;17(8):739–43.
29. Ohayon MM, Li KK, Guilleminault C. Risk factors for sleep bruxism in the general population. *Chest* 2001;119(1):53–61.
30. Simola P, Niskakangas M, Liukkonen K, et al. Sleep problems and daytime tiredness in Finnish preschool-aged children—a community survey. *Child Care Health Dev* 2010;36(6):805–11.
31. Castelo PM, Barbosa TS, Gaviao MB. Quality of life evaluation of children with sleep bruxism. *BMC Oral Health* 2010;10:16.
32. Strausz T, Ahlberg J, Lobbezoo F, et al. Awareness of tooth grinding and clenching from adolescence to young adulthood: a nine-year follow-up. *J Oral Rehabil* 2010;37(7):497–500.
33. Serra-Negra JM, Paiva SM, Seabra AP, et al. Prevalence of sleep bruxism in a group of Brazilian school children. *Eur Arch Paediatr Dent* 2010;11(4):192–5.
34. Laberge L, Tremblay RE, Vitaro F, et al. Development of parasomnias from childhood to early adolescence. *Pediatrics* 2000;106(1 Pt 1):67–74.

35. Petit D, Touchette E, Tremblay RE, et al. Dyssomnias and parasomnias in early childhood. *Pediatrics* 2007;119(5):e1016–25.
36. Cheifetz AT, Osganian SK, Allred EN, et al. Prevalence of bruxism and associated correlates in children as reported by parents. *J Dent Child (Chic)* 2005; 72(2):67–73.
37. Ng DK, Kwok KL, Cheung JM, et al. Prevalence of sleep problems in Hong Kong primary school children: a community-based telephone survey. *Chest* 2005; 128(3):1315–23.
38. Carlsson GE, Egermark I, Magnusson T. Predictors of bruxism, other oral parafunctions, and tooth wear over a 20-year follow-up period. *J Orofac Pain* 2003; 17(1):50–7.
39. Agerberg G, Bergenholtz A. Craniomandibular disorders in adult populations of West Bothnia, Sweden. *Acta Odontol Scand* 1989;47(3):129–40.
40. Mobilio N, Casetta I, Cesnik E, et al. Prevalence of self-reported symptoms related to temporomandibular disorders in an Italian population. *J Oral Rehabil* 2011;38(12):884–90.
41. Glaros AG. Incidence of diurnal and nocturnal bruxism. *J Prosthet Dent* 1981; 45(5):545–9.
42. Lavigne GJ, Huynh N, Kato T, et al. Genesis of sleep bruxism: motor and autonomic-cardiac interactions. *Arch Oral Biol* 2007;52(4):381–4.
43. Gastaldo E, Quatralle R, Graziani A, et al. The excitability of the trigeminal motor system in sleep bruxism: a transcranial magnetic stimulation and brainstem reflex study. *J Orofac Pain* 2006;20(2):145–55.
44. Lavigne GJ, Kato T, Kolta A, et al. Neurobiological mechanisms involved in sleep bruxism. *Crit Rev Oral Biol Med* 2003;14(1):30–46.
45. Kato T, Thie NM, Huynh N, et al. Topical review: sleep bruxism and the role of peripheral sensory influences. *J Orofac Pain* 2003;17(3):191–213.
46. Lobbezoo F, Naeije M. Bruxism is mainly regulated centrally, not peripherally. *J Oral Rehabil* 2001;28(12):1085–91.
47. Lavigne G, Toumlehto H, Macaluso GM. Pathophysiology of sleep bruxism. In: Lavigne GJ, Cistulli PA, Smith MT, editors. *Sleep medicine for dentists. A practical overview*. Hanover Park (IL): Quintessence Publishing Co, Inc; 2009. p. 117–24.
48. Macaluso GM, Guerra P, Di Giovanni G, et al. Sleep bruxism is a disorder related to periodic arousals during sleep. *J Dent Res* 1998;77(4):565–73.
49. Reding GR, Zepelin H, Robinson JE Jr, et al. Nocturnal teeth-grinding: all-night psychophysiological studies. *J Dent Res* 1968;47(5):786–97.
50. Satoh T, Harada Y. Tooth-grinding during sleep as an arousal reaction. *Experientia* 1971;27(7):785–6.
51. Satoh T, Harada Y. Electrophysiological study on tooth-grinding during sleep. *Electroencephalogr Clin Neurophysiol* 1973;35(3):267–75.
52. Huynh N, Kato T, Rompre PH, et al. Sleep bruxism is associated to micro-arousals and an increase in cardiac sympathetic activity. *J Sleep Res* 2006; 15(3):339–46.
53. Kato T, Montplaisir JY, Guitard F, et al. Evidence that experimentally induced sleep bruxism is a consequence of transient arousal. *J Dent Res* 2003;82(4): 284–8.
54. Terzano MG, Parrino L. Origin and significance of the cyclic alternating pattern (CAP). Review article. *Sleep Med Rev* 2000;4(1):101–23.
55. Parrino L, Ferri R, Bruni O, et al. Cyclic alternating pattern (CAP): the marker of sleep instability. *Sleep Med Rev* 2012;16(1):27–45.

56. Carra MC, Macaluso GM, Rompre PH, et al. Clonidine has a paradoxical effect on cyclic arousal and sleep bruxism during NREM sleep. *Sleep* 2010;33(12):1711–6.
57. Marthol H, Reich S, Jacke J, et al. Enhanced sympathetic cardiac modulation in bruxism patients. *Clin Auton Res* 2006;16(4):276–80.
58. Khoury S, Rouleau GA, Rompre PH, et al. A significant increase in breathing amplitude precedes sleep bruxism. *Chest* 2008;134(2):332–7.
59. Nashed A, Lanfranchi P, Rompré P, et al. Sleep bruxism is associated with a rise in arterial blood pressure. *Sleep* 2012;35(4), in press.
60. Miyawaki S, Lavigne GJ, Pierre M, et al. Association between sleep bruxism, swallowing-related laryngeal movement, and sleep positions. *Sleep* 2003;26(4):461–5.
61. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. *Nature* 2005;437(7063):1257–63.
62. Magee KR. Bruxism related to levodopa therapy. *JAMA* 1970;214(1):147.
63. Lavigne GJ, Soucy JP, Lobbezoo F, et al. Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism. *Clin Neuropharmacol* 2001;24(3):145–9.
64. Lobbezoo F, Lavigne GJ, Tanguay R, et al. The effect of catecholamine precursor L-dopa on sleep bruxism: a controlled clinical trial. *Mov Disord* 1997;12(1):73–8.
65. Lobbezoo F, Soucy JP, Montplaisir JY, et al. Striatal D2 receptor binding in sleep bruxism: a controlled study with iodine-123-iodobenzamide and single-photon-emission computed tomography. *J Dent Res* 1996;75(10):1804–10.
66. McCarley RW. Neurobiology of REM and NREM sleep. *Sleep Med* 2007;8(4):302–30.
67. Huynh N, Lavigne GJ, Lanfranchi PA, et al. The effect of 2 sympatholytic medications—propranolol and clonidine—on sleep bruxism: experimental randomized controlled studies. *Sleep* 2006;29(3):307–16.
68. Pal D, Mallick BN. Neural mechanism of rapid eye movement sleep generation with reference to REM-OFF neurons in locus coeruleus. *Indian J Med Res* 2007;125(6):721–39.
69. Reding GR, Rubright WC, Zimmerman SO. Incidence of bruxism. *J Dent Res* 1966;45(4):1198–204.
70. Lindqvist B. Bruxism in twins. *Acta Odontol Scand* 1974;32(3):177–87.
71. Hublin C, Kaprio J, Partinen M, et al. Sleep bruxism based on self-report in a nationwide twin cohort. *J Sleep Res* 1998;7(1):61–7.
72. Hublin C, Kaprio J. Genetic aspects and genetic epidemiology of parasomnias. *Sleep Med Rev* 2003;7(5):413–21.
73. Faraco J, Mignot E. Genetics of sleep and sleep disorders in humans. In: Kryger MH, Roth T, Dement WC, editors. *Principles and practice of sleep medicine*. 5th edition. St Louis (MO): Elsevier Saunders; 2011. p. 184–98.
74. Landolt H, Dijk DJ. Genetic basis of sleep in healthy humans. In: Kryger MH, Roth T, Dement WC, editors. *Principles and practice of sleep medicine*. 5th edition. St Louis (MO): Elsevier Saunders; 2011. p. 175–83.
75. Winocur E, Uziel N, Lisha T, et al. Self-reported bruxism - associations with perceived stress, motivation for control, dental anxiety and gagging. *J Oral Rehabil* 2011;38(1):3–11.
76. Manfredini D, Lobbezoo F. Role of psychosocial factors in the etiology of bruxism. *J Orofac Pain* 2009;23(2):153–66.
77. Pingitore G, Chrobak V, Petrie J. The social and psychologic factors of bruxism. *J Prosthet Dent* 1991;65(3):443–6.

78. Schneider C, Schaefer R, Ommerborn MA, et al. Maladaptive coping strategies in patients with bruxism compared to non-bruxing controls. *Int J Behav Med* 2007;14(4):257–61.
79. Sato C, Sato S, Takashina H, et al. Bruxism affects stress responses in stressed rats. *Clin Oral Investig* 2010;14(2):153–60.
80. Seraidarian P, Seraidarian PI, das Neves Cavalcanti B, et al. Urinary levels of catecholamines among individuals with and without sleep bruxism. *Sleep Breath* 2009;13(1):85–8.
81. Vanderas AP, Menenakou M, Kouimtzis T, et al. Urinary catecholamine levels and bruxism in children. *J Oral Rehabil* 1999;26(2):103–10.
82. Clark GT, Rugh JD, Handelman SL. Nocturnal masseter muscle activity and urinary catecholamine levels in bruxers. *J Dent Res* 1980;59(10):1571–6.
83. Major M, Rompre PH, Guitard F, et al. A controlled daytime challenge of motor performance and vigilance in sleep bruxers. *J Dent Res* 1999;78(11):1754–62.
84. Giraki M, Schneider C, Schafer R, et al. Correlation between stress, stress-coping and current sleep bruxism. *Head Face Med* 2010;6:2.
85. Katayoun E, Sima F, Naser V, et al. Study of the relationship of psychosocial disorders to bruxism in adolescents. *J Indian Soc Pedod Prev Dent* 2008;26(Suppl 3):S91–7.
86. Restrepo CC, Vasquez LM, Alvarez M, et al. Personality traits and temporomandibular disorders in a group of children with bruxing behaviour. *J Oral Rehabil* 2008;35(8):585–93.
87. Serra-Negra JM, Ramos-Jorge ML, Flores-Mendoza CE, et al. Influence of psychosocial factors on the development of sleep bruxism among children. *Int J Paediatr Dent* 2009;19(5):309–17.
88. Adams RD, Victor M. Principle of neurology. 5th edition. New York: McGraw-Hill, Inc; 1993. p. 348.
89. Winocur E, Gavish A, Voikovitch M, et al. Drugs and bruxism: a critical review. *J Orofac Pain* 2003;17(2):99–111.
90. Winocur E, Gavish A, Volfin G, et al. Oral motor parafunctions among heavy drug addicts and their effects on signs and symptoms of temporomandibular disorders. *J Orofac Pain* 2001;15(1):56–63.
91. Dinis-Oliveira RJ, Caldas I, Carvalho F, et al. Bruxism after 3,4-methylenedioxymethamphetamine (ecstasy) abuse. *Clin Toxicol (Phila)* 2010;48(8):863–4.
92. Sabuncuoğlu O, Ekinçi O, Berkem M. Fluoxetine-induced sleep bruxism in an adolescent treated with buspirone: a case report. *Spec Care Dentist* 2009;29(5):215–7.
93. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. *Ann Pharmacother* 1998;32(6):692–8.
94. Romanelli F, Adler DA, Bungay KM. Possible paroxetine-induced bruxism. *Ann Pharmacother* 1996;30(11):1246–8.
95. Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. *J Clin Psychiatry* 1993;54(11):432–4.
96. Lavigne GL, Lobbezoo F, Rompre PH, et al. Cigarette smoking as a risk factor or an exacerbating factor for restless legs syndrome and sleep bruxism. *Sleep* 1997;20(4):290–3.
97. Amir I, Hermesh H, Gavish A. Bruxism secondary to antipsychotic drug exposure: a positive response to propranolol. *Clin Neuropharmacol* 1997;20(1):86–9.

98. Rintakoski K, Ahlberg J, Hublin C, et al. Bruxism is associated with nicotine dependence: a nationwide Finnish twin cohort study. *Nicotine Tob Res* 2010; 12(12):1254–60.
99. Madrid G, Madrid S, Vranesh JG, et al. Cigarette smoking and bruxism. *Percept Mot Skills* 1998;87(3 Pt 1):898.
100. Silvestri R, Gagliano A, Arico I, et al. Sleep disorders in children with attention-deficit/hyperactivity disorder (ADHD) recorded overnight by video-polysomnography. *Sleep Med* 2009;10(10):1132–8.
101. Herrera M, Valencia I, Grant M, et al. Bruxism in children: effect on sleep architecture and daytime cognitive performance and behavior. *Sleep* 2006;29(9):1143–8.
102. Tan EK, Jankovic J, Ondo W. Bruxism in Huntington's disease. *Mov Disord* 2000; 15(1):171–3.
103. Srivastava T, Ahuja M, Srivastava M, et al. Bruxism as presenting feature of Parkinson's disease. *J Assoc Physicians India* 2002;50:457.
104. Kwak YT, Han IW, Lee PH, et al. Associated conditions and clinical significance of awake bruxism. *Geriatr Gerontol Int* 2009;9(4):382–90.
105. Stewart JT, Thomas JE, Williams LS. Severe bruxism in a demented patient. *South Med J* 1993;86(4):476–7.
106. Trevathan E, Naidu S. The clinical recognition and differential diagnosis of Rett syndrome. *J Child Neurol* 1988;3(Suppl):S6–16.
107. Meletti S, Cantalupo G, Volpi L, et al. Rhythmic teeth grinding induced by temporal lobe seizures. *Neurology* 2004;62(12):2306–9.
108. Bisulli F, Vignatelli L, Naldi I, et al. Increased frequency of arousal parasomnias in families with nocturnal frontal lobe epilepsy: a common mechanism? *Epilepsia* 2010;51(9):1852–60.
109. Tinuper P, Provini F, Bisulli F, et al. Movement disorders in sleep: guidelines for differentiating epileptic from non-epileptic motor phenomena arising from sleep. *Sleep Med Rev* 2007;11(4):255–67.
110. Miyawaki S, Tanimoto Y, Araki Y, et al. Association between nocturnal bruxism and gastroesophageal reflux. *Sleep* 2003;26(7):888–92.
111. Lucchesi LM, Speciali JG, Santos-Silva R, et al. Nocturnal awakening with headache and its relationship with sleep disorders in a population-based sample of adult inhabitants of Sao Paulo City, Brazil. *Cephalalgia* 2010;30(12):1477–85.
112. Montplaisir J, Lapierre O, Lavigne G. The restless leg syndrome: a condition associated with periodic or aperiodic slowing of the EEG. *Neurophysiol Clin* 1994;24(2):131–40 [in French].
113. Miller VA, Palermo TM, Powers SW, et al. Migraine headaches and sleep disturbances in children. *Headache* 2003;43(4):362–8.
114. Sjöholm TT, Lowe AA, Miyamoto K, et al. Sleep bruxism in patients with sleep-disordered breathing. *Arch Oral Biol* 2000;45(10):889–96.
115. Sforza E, Zucconi M, Petronelli R, et al. REM sleep behavioral disorders. *Eur Neurol* 1988;28(5):295–300.
116. Reutens S, Sachdev PS. Periodic limb movements and other movement disorders in sleep: neuropsychiatric dimensions. *Int Rev Psychiatry* 2005;17(4):283–92.
117. Bader G, Lavigne G. Sleep bruxism; an overview of an oromandibular sleep movement disorder. Review article. *Sleep Med Rev* 2000;4(1):27–43.
118. Camparis CM, Siqueira JT. Sleep bruxism: clinical aspects and characteristics in patients with and without chronic orofacial pain. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006;101(2):188–93.

119. Rossetti LM, Pereira de Araujo Cdos R, Rossetti PH, et al. Association between rhythmic masticatory muscle activity during sleep and masticatory myofascial pain: a polysomnographic study. *J Orofac Pain* 2008;22(3):190–200.
120. Bruni O, Fabrizi P, Ottaviano S, et al. Prevalence of sleep disorders in childhood and adolescence with headache: a case-control study. *Cephalalgia* 1997;17(4):492–8.
121. Nagamatsu-Sakaguchi C, Minakuchi H, Clark GT, et al. Relationship between the frequency of sleep bruxism and the prevalence of signs and symptoms of temporomandibular disorders in an adolescent population. *Int J Prosthodont* 2008;21(4):292–8.
122. Huynh N, Khoury S, Rompré PH, et al. Prevalence of headache and neck pain in a sleep bruxism population investigated in a sleep laboratory. *Sleep* 2006; 29(Abstract Suppl):A282.
123. Svensson P, Burgaard A, Schlosser S. Fatigue and pain in human jaw muscles during a sustained, low-intensity clenching task. *Arch Oral Biol* 2001;46(8):773–7.
124. Glaros AG, Burton E. Parafunctional clenching, pain, and effort in temporomandibular disorders. *J Behav Med* 2004;27(1):91–100.
125. McMillan AS, Lawson ET. Effect of tooth clenching and jaw opening on pain-pressure thresholds in the human jaw muscles. *J Orofac Pain* 1994;8(3):250–7.
126. Magnusson T, Egermark I, Carlsson GE. A longitudinal epidemiologic study of signs and symptoms of temporomandibular disorders from 15 to 35 years of age. *J Orofac Pain* 2000;14(4):310–9.
127. Velly AM, Gornitsky M, Philippe P. Contributing factors to chronic myofascial pain: a case-control study. *Pain* 2003;104(3):491–9.
128. Macfarlane TV, Kenealy P, Kingdon HA, et al. Orofacial pain in young adults and associated childhood and adulthood factors: results of the population study, Wales, United Kingdom. *Community Dent Oral Epidemiol* 2009;37(5):438–50.
129. Pereira LJ, Costa RC, Franca JP, et al. Risk indicators for signs and symptoms of temporomandibular dysfunction in children. *J Clin Pediatr Dent* 2009;34(1):81–6.
130. Pereira LJ, Pereira-Cenci T, Del Bel Cury AA, et al. Risk indicators of temporomandibular disorder incidences in early adolescence. *Pediatr Dent* 2010; 32(4):324–8.
131. Rugh JD, Harlan J. Nocturnal bruxism and temporomandibular disorders. *Adv Neurol* 1988;49:329–41.
132. Goulet JP, Clark GT, Flack VF, et al. The reproducibility of muscle and joint tenderness detection methods and maximum mandibular movement measurement for the temporomandibular system. *J Orofac Pain* 1998;12(1):17–26.
133. Barbosa Tde S, Miyakoda LS, Pocztaruk Rde L, et al. Temporomandibular disorders and bruxism in childhood and adolescence: review of the literature. *Int J Pediatr Otorhinolaryngol* 2008;72(3):299–314.
134. Miyake R, Ohkubo R, Takehara J, et al. Oral parafunctions and association with symptoms of temporomandibular disorders in Japanese university students. *J Oral Rehabil* 2004;31(6):518–23.
135. Dao TT, Lund JP, Lavigne GJ. Comparison of pain and quality of life in bruxers and patients with myofascial pain of the masticatory muscles. *J Orofac Pain* 1994;8(4):350–6.
136. Glaros AG, Williams K, Lausten L. Diurnal variation in pain reports in temporomandibular disorder patients and control subjects. *J Orofac Pain* 2008;22(2):115–21.
137. Vendrame M, Kaleyias J, Valencia I, et al. Polysomnographic findings in children with headaches. *Pediatr Neurol* 2008;39(1):6–11.

138. Lavigne G, Palla S. Transient morning headache: recognizing the role of sleep bruxism and sleep-disordered breathing. *J Am Dent Assoc* 2010; 141(3):297–9.
139. Zarowski M, Mlodzikowska-Albrecht J, Steinborn B. The sleep habits and sleep disorders in children with headache. *Adv Med Sci* 2007;52(Suppl 1):194–6.
140. Biondi DM. Headaches and their relationship to sleep. *Dent Clin North Am* 2001; 45(4):685–700.
141. Bailey DR. Tension headache and bruxism in the sleep disordered patient. *Cranio* 1990;8(2):174–82.
142. Macfarlane TV, Gray RJ, Kincey J, et al. Factors associated with the temporomandibular disorder, pain dysfunction syndrome (PDS): Manchester case-control study. *Oral Dis* 2001;7(6):321–30.
143. Olesen J, Lipton RB. Headache classification update 2004. *Curr Opin Neurol* 2004;17:275–82.
144. Isik U, Ersu RH, Ay P, et al. Prevalence of headache and its association with sleep disorders in children. *Pediatr Neurol* 2007;36(3):146–51.
145. Liljestrom MR, Le Bell Y, Anttila P, et al. Headache children with temporomandibular disorders have several types of pain and other symptoms. *Cephalalgia* 2005;25(11):1054–60.
146. Sheldon SH. Obstructive sleep apnea and bruxism in children. *Sleep Med Clin* 2010;5(1):163–8.
147. Eitner S, Urschitz MS, Guenther A, et al. Sleep problems and daytime somnolence in a German population-based sample of snoring school-aged children. *J Sleep Res* 2007;16(1):96–101.
148. Grechi TH, Trawitzki LV, de Felicio CM, et al. Bruxism in children with nasal obstruction. *Int J Pediatr Otorhinolaryngol* 2008;72(3):391–6.
149. DiFrancesco RC, Junqueira PA, Trezza PM, et al. Improvement of bruxism after T & A surgery. *Int J Pediatr Otorhinolaryngol* 2004;68(4):441–5.
150. Eftekharian A, Raad N, Gholami-Ghasri N. Bruxism and adenotonsillectomy. *Int J Pediatr Otorhinolaryngol* 2008;72(4):509–11.
151. Oksenberg A, Arons E. Sleep bruxism related to obstructive sleep apnea: the effect of continuous positive airway pressure. *Sleep Med* 2002;3(6):513–5.
152. Thie NM, Kato T, Bader G, et al. The significance of saliva during sleep and the relevance of oromotor movements. *Sleep Med Rev* 2002;6(3):213–27.
153. Huynh N, Manzini C, Rompre PH, et al. Weighing the potential effectiveness of various treatments for sleep bruxism. *J Can Dent Assoc* 2007;73(8):727–30.
154. Shulman J. Teaching patients how to stop bruxing habits. *J Am Dent Assoc* 2001;132(9):1275–7.
155. Jadidi F, Castrillon E, Svensson P. Effect of conditioning electrical stimuli on temporalis electromyographic activity during sleep. *J Oral Rehabil* 2008;35(3): 171–83.
156. Ommerborn MA, Schneider C, Giraki M, et al. Effects of an occlusal splint compared with cognitive-behavioral treatment on sleep bruxism activity. *Eur J Oral Sci* 2007;115(1):7–14.
157. Wieselmann-Penkner K, Janda M, Lorenzoni M, et al. A comparison of the muscular relaxation effect of TENS and EMG-biofeedback in patients with bruxism. *J Oral Rehabil* 2001;28(9):849–53.
158. Lobbezoo F, van der Zaag J, van Selms MK, et al. Principles for the management of bruxism. *J Oral Rehabil* 2008;35(7):509–23.
159. Macedo CR, Silva AB, Machado MA, et al. Occlusal splints for treating sleep bruxism (tooth grinding). *Cochrane Database Syst Rev* 2007;4:CD005514.

160. Nascimento LL, Amorim CF, Giannasi LC, et al. Occlusal splint for sleep bruxism: an electromyographic associated to Helkimo index evaluation. *Sleep Breath* 2008;12(3):275–80.
161. Harada T, Ichiki R, Tsukiyama Y, et al. The effect of oral splint devices on sleep bruxism: a 6-week observation with an ambulatory electromyographic recording device. *J Oral Rehabil* 2006;33(7):482–8.
162. Dube C, Rompre PH, Manzini C, et al. Quantitative polygraphic controlled study on efficacy and safety of oral splint devices in tooth-grinding subjects. *J Dent Res* 2004;83(5):398–403.
163. Okeson JP. The effects of hard and soft occlusal splints on nocturnal bruxism. *J Am Dent Assoc* 1987;114(6):788–91.
164. Daif ET. Correlation of splint therapy outcome with the electromyography of masticatory muscles in temporomandibular disorder with myofascial pain. *Acta Odontol Scand* 2012;70(1):72–7.
165. Stapelmann H, Turp JC. The NTI-tss device for the therapy of bruxism, temporomandibular disorders, and headache - where do we stand? A qualitative systematic review of the literature. *BMC Oral Health* 2008;8:22.
166. Jokstad A, Mo A, Krogstad BS. Clinical comparison between two different splint designs for temporomandibular disorder therapy. *Acta Odontol Scand* 2005; 63(4):218–26.
167. Jokstad A. The NTI-tss device may be used successfully in the management of bruxism and TMD. *Evid Based Dent* 2009;10(1):23.
168. Scrivani SJ, Keith DA, Kaban LB. Temporomandibular disorders. *N Engl J Med* 2008;359(25):2693–705.
169. Al-Ani MZ, Davies SJ, Gray RJ, et al. Stabilisation splint therapy for temporomandibular pain dysfunction syndrome. *Cochrane Database Syst Rev* 2004;1: CD002778.
170. Friction J. Myogenous temporomandibular disorders: diagnostic and management considerations. *Dent Clin North Am* 2007;51(1):61–83, vi.
171. Dao TT, Lavigne GJ. Oral splints: the crutches for temporomandibular disorders and bruxism? *Crit Rev Oral Biol Med* 1998;9(3):345–61.
172. Friction J. Current evidence providing clarity in management of temporomandibular disorders: summary of a systematic review of randomized clinical trials for intra-oral appliances and occlusal therapies. *J Evid Based Dent Pract* 2006; 6(1):48–52.
173. de Felicio CM, de Oliveira MM, da Silva MA. Effects of orofacial myofunctional therapy on temporomandibular disorders. *Cranio* 2010;28(4):249–59.
174. De Boever JA, Nilner M, Orthlieb JD, et al. Recommendations by the EACD for examination, diagnosis, and management of patients with temporomandibular disorders and orofacial pain by the general dental practitioner. *J Orofac Pain* 2008;22(3):268–78.
175. Gagnon Y, Mayer P, Morisson F, et al. Aggravation of respiratory disturbances by the use of an occlusal splint in apneic patients: a pilot study. *Int J Prosthodont* 2004;17(4):447–53.
176. Landry-Schonbeck A, de Grandmont P, Rompre PH, et al. Effect of an adjustable mandibular advancement appliance on sleep bruxism: a crossover sleep laboratory study. *Int J Prosthodont* 2009;22(3):251–9.
177. Landry ML, Rompre PH, Manzini C, et al. Reduction of sleep bruxism using a mandibular advancement device: an experimental controlled study. *Int J Prosthodont* 2006;19(6):549–56.

178. Franco L, Rompre PH, de Grandmont P, et al. A mandibular advancement appliance reduces pain and rhythmic masticatory muscle activity in patients with morning headache. *J Orofac Pain* 2011;25(3):240–9.
179. Martinez-Gomis J, Willaert E, Nogues L, et al. Five years of sleep apnea treatment with a mandibular advancement device. Side effects and technical complications. *Angle Orthod* 2010;80(1):30–6.
180. de Almeida FR, Lowe AA, Tsuiiki S, et al. Long-term compliance and side effects of oral appliances used for the treatment of snoring and obstructive sleep apnea syndrome. *J Clin Sleep Med* 2005;1(2):143–52.
181. Saletu A, Parapatics S, Saletu B, et al. On the pharmacotherapy of sleep bruxism: placebo-controlled polysomnographic and psychometric studies with clonazepam. *Neuropsychobiology* 2005;51(4):214–25.
182. Saletu A, Parapatics S, Anderer P, et al. Controlled clinical, polysomnographic and psychometric studies on differences between sleep bruxers and controls and acute effects of clonazepam as compared with placebo. *Eur Arch Psychiatry Clin Neurosci* 2010;260(2):163–74.
183. Stein DJ, Van Greunen G, Niehaus D. Can bruxism respond to serotonin reuptake inhibitors? *J Clin Psychiatry* 1998;59(3):133.
184. Brown ES, Hong SC. Antidepressant-induced bruxism successfully treated with gabapentin. *J Am Dent Assoc* 1999;130(10):1467–9.
185. Mowla A, Sabayan B. Topiramate for bruxism: report of 2 cases. *J Clin Psychopharmacol* 2010;30(3):346–7.
186. Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. *J Am Dent Assoc* 2000;131(2):211–6.
187. Lee SJ, McCall WD Jr, Kim YK, et al. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. *Am J Phys Med Rehabil* 2010;89(1):16–23.
188. Lobbezoo F, Soucy JP, Hartman NG, et al. Effects of the D2 receptor agonist bromocriptine on sleep bruxism: report of two single-patient clinical trials. *J Dent Res* 1997;76(9):1610–4.
189. Raigrodski AJ, Christensen LV, Mohamed SE, et al. The effect of four-week administration of amitriptyline on sleep bruxism. A double-blind crossover clinical study. *Cranio* 2001;19(1):21–5.
190. Mohamed SE, Christensen LV, Penchas J. A randomized double-blind clinical trial of the effect of amitriptyline on nocturnal masseteric motor activity (sleep bruxism). *Cranio* 1997;15(4):326–32.
191. Van der Zaag J, Lobbezoo F, Van der Avoort PG, et al. Effects of pergolide on severe sleep bruxism in a patient experiencing oral implant failure. *J Oral Rehabil* 2007;34(5):317–22.
192. Kast RE. Tiagabine may reduce bruxism and associated temporomandibular joint pain. *Anesth Prog* 2005;52(3):102–4.
193. Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. *J Clin Psychiatry* 1999;60(12):857–60.